Роль нейропептидов (окситоцин, вазопрессин, нейропептид S) в развитии когнитивных нарушений при болезни Альцгеймера

С каждым годом количество людей с диагностированной болезнью Альцгеймера стремительно увеличивается. Несмотря на многочисленные исследования, подобрать терапию, которая бы надежно замедляла течение болезни и приводила бы к полному излечению, не удалось. В таком случае любое рассмотрение вопроса, касающееся поиска лекарственных веществ для коррекции когнитивных и психоэмоциональных нарушений при развитии болезни Альцгеймера, является актуальной проблемой, заслуживающей особого внимания.

Проводился сбор статей из базы данных PubMed, опубликованных за последние 10 лет. Целью настоящего обзора является анализ последних экспериментальных данных и результатов, касающихся взаимосвязи между болезнью Альцгеймера и активностью таких нейропептидов, как окситоцин, вазопрессин и нейропептид S, а также описывающих эффекты, которые возникают при их введении. Это позволит более полно понять проблематику и обеспечит актуализацию сведений по данному вопросу. Наиболее подробно рассматривается способность нейропептидов восстанавливать нарушенные когнитивные функции у лабораторных животных с моделью болезни Альцгеймера.

Детально изложенная информация о наличии взаимосвязи и положительном влиянии изучаемых нейропептидов на болезнь Альцгеймера позволяет рассматривать данные нейропептиды в качестве потенциальных лекарственных препаратов для лечения данного заболевания.

1. Lane C.A., Hardy J., Schott J.M. Alzheimer’s disease. Eur. J. Neurol. 2018;25(1):59–70. DOI: 10.1111/ene.13439.

2. Athar T., Al Balushi K., Khan S.A. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Mol. Biol. Rep.2021;48(7):5629–5645. DOI: 10.1007/s11033-021-06512-9.

3. Breijyeh Z., Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020;25(24):5789. DOI: 10.3390/molecules25245789.

4. Mantzavinos V., Alexiou A. Biomarkers for Alzheimer’s disease diagnosis. Curr. Alzheimer Res. 2017;14(11):1149–1154. DOI: 10.2174/1567205014666170203125942.

5. Grossberg G.T., Tong G., Burke A.D., Tariot P.N. Present algorithms and future treatments for Alzheimer’s disease. J. Alzheimers Dis. 2019;67(4):1157–1171. DOI: 10.3233/JAD-180903.

6. Briggs R., Kennelly S.P., O’Neill D. Drug treatments in Alzheimer’s disease. Clin. Med. (Lond.). 2016;16(3):247–253. DOI: 10.7861/clinmedicine.16-3-247.

7. Bordt E.A., Smith C.J., Demarest T.G., Bilbo S.D., Kingsbury M.A. Mitochondria, oxytocin, and vasopressin: unfolding the inflammatory protein response. Neurotoxicity Res. 2019;36(2):239–256. DOI: 10.1007/s12640-018-9962-7.

8. Szczepanska-Sadowska E., Wsol A., Cudnoch-Jedrzejewska A., Czarzasta K., Żera T. Multiple aspects of inappropriate action of renin-angiotensin, vasopressin, and oxytocin systems in neuropsychiatric and neurodegenerative diseases. J. Clin. Med. 2022;11(4):908. DOI: 10.3390/jcm11040908.

9. Caldwell H.K. Oxytocin and vasopressin: powerful regulators of social behavior. Neuroscientist. 2017;23(5):517–528. DOI: 10.1177/1073858417708284.

10. Dumais K.M., Veenema A.H. Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior. Front. Neuroendocrinol. 2016;40:1–23. DOI: 10.1016/j.yfrne.2015.04.003.

11. McCormack S.E., Blevins J.E., Lawson E.A. Metabolic effects of oxytocin. Endocr. Rev. 2020;41(2):121–145. DOI: 10.1210/endrev/bnz012.

12. Kerem L., Lawson E.A. The effects of oxytocin on appetite regulation, food intake and metabolism in humans. Int. J. Mol. Sci. 2021;22(14):7737. DOI: 10.3390/ijms22147737.

13. Ludwig M., Apps D., Menzies J., Patel J.C., Rice M.E. Dendritic release of neurotransmitters. Compr. Physiol. 2016;7(1):235–252. DOI: 10.1002/cphy.c160007.

14. Johnson Z.V., Young L.J. Oxytocin and vasopressin neural networks: Implications for social behavioral diversity and translational neuroscience. Neurosci. Biobehav. Rev. 2017;76(Pt.A):87–98. DOI: 10.1016/j.neubiorev.2017.01.034.

15. Abramova O., Zorkina Y., Ushakova V., Zubkov E., Morozova A., Chekhonin V. The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders. Neuropeptides. 2020;83:102079. DOI: 10.1016/j.npep.2020.102079.

16. Cilz N.I., Cymerblit-Sabba A., Young W.S. Oxytocin and vasopressin in the rodent hippocampus. Genes Brain Behav. 2019;18(1):e12535. DOI: 10.1111/gbb.12535.

17. Carter C.S., Kenkel W.M., MacLean E.L., Wilson S.R., Perkeybile A.M., Yee J.R. et al. Is oxytocin “nature’s medicine”? Pharmacol. Rev. 2020;72(4):829–861. DOI: 10.1124/pr.120.019398.

18. Pekarek B.T., Kochukov M., Lozzi B., Wu T., Hunt P.J., Tepe B. et al. Oxytocin signaling is necessary for synaptic maturation of adult-born neurons. Genes Dev. 2022;36(21- 24):1100–1118. DOI: 10.1101/gad.349930.122.

19. Bidzan L., Bidzan M., Pąchalska M. Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia. Med. Sci. Monit. 2012;18(3):CR182–189. DOI: 10.12659/msm.882523.

20. Cárdenas J., Blanca M.J., Carvajal F., Rubio S., Pedraza C. Emotional processing in healthy ageing, mild cognitive impairment, and Alzheimer’s disease. Int. J. Environ. Res. Public Health. 2021;18(5):2770. DOI: 10.3390/ijerph18052770.

21. Duan Y., Lu L., Chen J., Wu C., Liang J., Zheng Y. et al. Psychosocial interventions for Alzheimer’s disease cognitive symptoms: a Bayesian network meta-analysis. BMC Geriatr. 2018;18(1):175. DOI: 10.1186/s12877-018-0864-6.

22. Caldwell H.K., Albers H.E. Oxytocin, vasopressin, and the motivational forces that drive social behaviors. Curr. Top Behav. Neurosci. 2016;27:51–103. DOI: 10.1007/7854_2015_390.

23. Lin Y.T., Hsieh T.Y., Tsai T.C., Chen C.C., Huang C.C., Hsu K.S. Conditional deletion of hippocampal CA2/CA3a oxytocin receptors impairs the persistence of long-term social recognition memory in mice. J. Neurosci. 2018;38(5):1218– 1231. DOI: 10.1523/JNEUROSCI.1896-17.2017.

24. Raam T., McAvoy K.M., Besnard A., Veenema A.H., Sahay A. Hippocampal oxytocin receptors are necessary for discrimination of social stimuli. Nat. Commun. 2017;8(1):2001. DOI: 10.1038/s41467-017-02173-0.

25. Takahashi J., Yamada D., Ueta Y., Iwai T., Koga E., Tanabe M. et al. Oxytocin reverses Aβ-induced impairment of hippocampal synaptic plasticity in mice. Biochem. Biophys. Res. Commun. 2020;528(1):174–178. DOI: 10.1016/j.bbrc.2020.04.046.

26. Takahashi J., Ueta Y., Yamada D., Sasaki-Hamada S., Iwai T., Akita T. et al. Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β-amyloid peptide (25-35)-induced memory impairment in mice. Neuropsychopharmacol. Rep. 2022;42(4):492– 501. DOI: 10.1002/npr2.12292.

27. Tanaka A., Furubayashi T., Arai M., Inoue D., Kimura S., Kiriyama A. et al. Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application. Mol. Pharm. 2018;15(3):1105–1111. DOI: 10.1021/acs.molpharmaceut.7b00991.

28. Quintana D.S., Lischke A., Grace S., Scheele D., Ma Y., Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol. Psychiatry. 2021;26(1):80–91. DOI: 10.1038/s41380-020-00864-7.

29. El-Ganainy S.O., Soliman O.A., Ghazy A.A., Allam M., Elbahnasi A.I., Mansour A.M. et al. Intranasal oxytocin attenuates cognitive impairment, β-amyloid burden and tau deposition in female rats with Alzheimer’s disease: interplay of ERK1/2/ GSK3β/caspase-3. Neurochem. Res. 2022;47(8):2345–2356. DOI: 10.1007/s11064-022-03624-x.

30. Lemke G., Huang Y. The dense-core plaques of Alzheimer’s disease are granulomas. J. Exp. Med. 2022;219(8):e20212477. DOI: 10.1084/jem.20212477.

31. Simpson D.S.A., Oliver P.L. ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants (Basel). 2020;9(8):743. DOI: 10.3390/antiox9080743.

32. Edler M.K., Mhatre-Winters I., Richardson J.R. Microglia in Aging and Alzheimer’s Disease: A Comparative Species Review. Cells. 2021;10(5):1138. DOI: 10.3390/cells10051138.

33. Selles M.C., Fortuna J.T.S., de Faria Y.P.R., Siqueira L.D., Lima-Filho R., Longo B.M. et al. Oxytocin attenuates microglial activation and restores social and non-social memory in APP/ PS1 Alzheimer model mice. iScience. 2023;26(4):106545. DOI: 10.1016/j.isci.2023.106545.

34. Горина Я.В., Салмина А.Б., Кувачева Н.В., Комлева Ю.К., Морозова Г.А., Демко И.В., Петрова М.М. Нейровоспаление и инсулинорезистентность при болезни Альцгеймера. Сибирскмедобозр. 2014;4:11–19.

35. Inoue T., Yamakage H., Tanaka M., Kusakabe T., Shimatsu A., Satoh-Asahara N. Oxytocin suppresses inflammatory responses induced by lipopolysaccharide through inhibition of the eIF-2-ATF4 pathway in mouse microglia. Cells. 2019;8(6):527. DOI: 10.3390/cells8060527.

36. Roth C.L., D’Ambrosio G., Elfers C. Activation of nuclear factor kappa B pathway and reduction of hypothalamic oxytocin following hypothalamic lesions. J. Syst. Integr. Neurosci. 2016;2(1):79–84. DOI: 10.15761/JSIN.1000114.

37. Yuan L., Liu S., Bai X., Gao Y., Liu G., Wang X. et al. Oxytocin inhibits lipopolysaccharide-induced inflammation in microglial cells and attenuates microglial activation in lipopolysaccharide-treated mice. J. Neuroinflammation. 2016;13(1):77. DOI: 10.1186/s12974-016-0541-7.

38. Huang Y., Happonen K.E., Burrola P.G., O’Connor C., Hah N., Huang L. et al. Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat. Immunol. 2021;22(5):586– 594. DOI: 10.1038/s41590-021-00913-5.

39. Van den Burg E.H., Stindl J., Grund T., Neumann I.D., Strauss O. Oxytocin stimulates extracellular Ca2+ influx through TRPV2 channels in hypothalamic neurons to exert its anxiolytic effects. Neuropsychopharmacology. 2015;40(13):2938–2947. DOI: 10.1038/npp.2015.147.

40. Zhang X., Zhao F., Wang C., Zhang J., Bai Y., Zhou F. et al. AVP(4-8) Improves cognitive behaviors and hippocampal synaptic plasticity in the APP/PS1 mouse model of Alzheimer’s disease. Neurosci. Bull. 2020;36(3):254–262. DOI: 10.1007/s12264-019-00434-0.

41. Finton C.J., Ophir A.G. Developmental exposure to intranasal vasopressin impacts adult prairie vole spatial memory. Psychoneuroendocrinology. 2022;141:105750. DOI: 10.1016/j.psyneuen.2022.105750.

42. Yang C., Zhang X., Gao J., Wang M., Yang Z. Arginine vasopressin ameliorates spatial learning impairments in chronic cerebral hypoperfusion via V1a receptor and autophagy signaling partially. Transl. Psychiatry. 2017;7(7):e1174. DOI: 10.1038/tp.2017.121.

43. Cymerblit-Sabba A., Walsh C., Duan K.Z., Song J., Holmes O., Young W.S. Simultaneous knockouts of the oxytocin and vasopressin 1b receptors in hippocampal CA2 impair social memory. BioRxiv. 2023;2023. DOI: 10.1101/2023.01.30.526271.

44. Varga J., Klausz B., Domokos Á., Kálmán S., Pákáski M., Szűcs S. et al. Increase in Alzheimer’s related markers preceeds memory disturbances: studies in vasopressin-deficient Brattleboro rat. Brain Res. Bull. 2014;100:6–13. DOI: 10.1016/j.brainresbull.2013.10.010.

45. Pan Y.F., Jia X.T., Wang X.H., Chen X.R., Li Q.S., Gao X.P. et al. Arginine vasopressin remolds the spontaneous discharges disturbed by amyloid β protein in hippocampal CA1 region of rats. Regul. Pept. 2013;183:7–12. DOI: 10.1016/j.regpep.2013.03.003.

46. Smith A.S., Williams Avram S.K., Cymerblit-Sabba A., Song J., Young W.S. Targeted activation of the hippocampal CA2 area strongly enhances social memory. Mol. Psychiatry. 2016;21(8):1137–1144. DOI: 10.1038/mp.2015.189.

47. Lukas M., Neumann I.D. Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects. Neuropharmacology. 2012;62(1):398–405. DOI: 10.1016/j.neuropharm.2011.08.016.

48. Zhao P., Qian X., Nie Y., Sun E., Wang Z., Wu J. et al. Neuropeptide S ameliorates cognitive impairment of APP/PS1 transgenic mice by promoting synaptic plasticity and reducing Aβ deposition. Front. Behav. Neurosci. 2019;13:138. DOI: 10.3389/fnbeh.2019.00138.

49. Liu X., Si W., Garau C., Jüngling K., Pape H.C., Schulz S., Reinscheid R.K. Neuropeptide S precursor knockout mice display memory and arousal deficits. Eur. J. Neurosci. 2017;46(1):1689–1700. DOI: 10.1111/ejn.13613.

50. Grund T., Neumann I.D. Neuropeptide S induces acute anxiolysis by phospholipase C-dependent signaling within the medial amygdala. Neuropsychopharmacology. 2018;43(5):1156– 1163. DOI: 10.1038/npp.2017.169.

51. Grund T., Goyon S., Li Y., Eliava M., Liu H., Charlet A. et al. Neuropeptide S activates paraventricular oxytocin neurons to induce anxiolysis. J. Neurosci. 2017;37(50):12214–12225. DOI: 10.1523/JNEUROSCI.2161-17.2017.

52. Han R.W., Zhang R.S., Xu H.J., Chang M., Peng Y.L., Wang R. Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ₁₋₄₂ in mice novel object and object location recognition tasks. Neuropharmacology. 2013;70:261–267. DOI: 10.1016/j.neuropharm.2013.02.002.

53. Han R.W., Xu H.J., Zhang R.S., Wang P., Chang M., Peng Y.L. et al. Neuropeptide S interacts with the basolateral amygdala noradrenergic system in facilitating object recognition memory consolidation. Neurobiol. Learn Mem. 2014;107:32–36. DOI: 10.1016/j.nlm.2013.10.010.

54. Li C., Wu X.J., Li W. Neuropeptide S promotes maintenance of newly formed dendritic spines and performance improvement after motor learning in mice. Peptides. 2022;156:170860. DOI: 10.1016/j.peptides.2022.170860.

55. Wang C., Xin L., Cai C.C., Cong C.Y., Xie J.F., Kong X.P. et al. Neuropeptide S displays as a key neuromodulator in olfactory spatial memory. Chem. Senses. 2020;45(3):195–202. DOI: 10.1093/chemse/bjaa003.